Dependence on key personnel
The company relies on a small number of people with specialized knowledge and creativity.
- Scope
- Product development and commercialization
- Materiality
- high
Ortoma
Ortoma is a Swedish medical technology company focused on AI-based systems for orthopedic surgery. Its core platform, OTS™, is designed for planning, navigation, and follow-up of implant and prosthesis procedures and is built to work across different implant suppliers and healthcare markets.
| % | |
|---|---|
| Hardware systems | 45% Operating-room hardware sold as part of the OTS™ solution. |
| Software licenses | 30% Recurring licenses for the OTS™ planning and navigation platform. |
| Consumables | 15% Single-use items consumed during orthopedic procedures. |
| Service and support | 10% Implementation, support, and related commercial services around the platform. |
Ortoma sells primarily through distributors and strategic partners, so its direct commercial counterparties are often...
- Hospitalsprimary
Buy OTS™ systems and licenses for orthopedic operating rooms to improve planning and navigation.
- Clinics and surgical centerssecondary
Use the platform for hip and other orthopedic procedures where workflow and precision matter.
- Distributors and strategic partnersprimary
Purchase and resell the solution, helping Ortoma reach markets and end users.
- Implant and medical device ecosystem partnerssecondary
Adopt compatible digital tools that can integrate with their implant offerings.
Ortoma develops its products for a global market and adapts commercialization to local reimbursement systems,...
- •Global product design with market-specific commercialization
- •Sales depend on local reimbursement and regulatory frameworks
- •Distribution partnerships are used to enter new countries
- •Market rollout can differ by healthcare system and adoption speed
- •Future revenue mix is expected to become more recurring across markets
Ortoma's strategy is to commercialize OTS™ through strategic partnerships and a distributor-led model that can scale...
01
Commercialize OTS™ through distributor partnershipsshort-term
Partners provide market access and reduce the need for a large direct sales footprint.
02
Grow recurring revenue mixmedium-term
Software licenses and consumables can create a more predictable revenue profile than one-time hardware sales.
03
Broaden the platform beyond OTS™ Hiplong-term
Additional indications can expand the addressable market and leverage the same technical platform.
Ortoma's business depends on successful commercialization, clinical adoption, and continued access to qualified...
Commercial adoption risk
Demand for current and future products may be lower or slower to develop than expected.
- Scope
- Sales and market rollout
- Materiality
- high
Data privacy and cybersecurity
The business may process sensitive personal and clinical data and could face breaches or compliance failures.
- Scope
- Patient data and connected systems
- Materiality
- medium
Funding and going-concern dependence
The company has historically depended on external capital until operations become self-funding.
- Scope
- Liquidity and development funding
- Materiality
- high
Market acceptance of new products
New launches may be outcompeted or fail to gain traction with hospitals and clinicians.
- Scope
- Product pipeline and expansion
- Materiality
- high
Foreign exchange exposure
Sales are made globally, with significant USD exposure while many costs are in SEK and EUR.
- Scope
- Transaction risk
- Materiality
- medium
Revenue recognition across hardware, licenses, and consumables
Mix shifts can change the share of recurring revenue and reported growth
Capitalized development expenditures
Amortization and impairment can materially affect earnings and equity
Patent and intangible asset impairment
Could create non-cash write-downs
Foreign currency effects
Can affect revenue, expenses, and net result period to period
: 11/08/2026